Publications

Authors:

Caocci, Giovanni; Mulas, Olga; Annunziata, Mario; Luciano, Luigiana; Abruzzese, Elisabetta; Bonifacio, Massimiliano; Orlandi, Ester Maria; Albano, Francesco; Galimberti, Sara; Iurlo, Alessandra; Pregno, Patrizia; Sgherza, Nicola; Martino, Bruno; Binotto, Gianni; Castagnetti, Fausto; Gozzini, Antonella; Bocchia, Monica; Fozza, Claudio; Stagno, Fabio; Simula, Maria Pina; De Gregorio, Fiorenza; Trawinska, Malgorzata Monika; Scaffidi, Luigi; Elena, Chiara; Attolico, Imma; Baratè, Claudia; Cattaneo, Daniele; Pirillo, Francesca; Gugliotta, Gabriele; Sicuranza, Anna; Molica, Matteo; La Nasa, Giorgio; Foà, Robin; Breccia, Massimo

Title:

Long-term mortality rate for cardiovascular disease in 656 chronic myeloid leukaemia patients treated with second- and third-generation tyrosine kinase inhibitors

Year:

2020

Type of item:

Articolo in Rivista

Tipologia ANVUR:

Articolo su rivista

Language:

Inglese

Referee:

No

Name of journal:

International Journal of Cardiology

ISSN of journal:

0167-5273

N° Volume:

301

Page numbers:

163-166

Keyword:

Cardiovascular toxicity; Chronic myeloid leuk; Ischemic heart disease; TKI; a; emia

Short description of contents:

Background: Limited information is available regarding the rate of long-term cardiovascular (CV) mortality in chronic myeloid leukaemia (CML) patients treated with second- and third-generation tyrosine kinase inhibitors (2nd(G)/3rd(G) TKIs) in the real-life practice.Methods: We identified 656 consecutive CML patients treated with nilotinib, dasatinib, bosutinib and ponatinib.Results: The 15-year CV-mortality free survival was 93 +/- 2.8%. Age >= 65 years (p = 0.005) and a positive history of CV disease (p = 0.04) were significantly associated with a lower CV-mortality free survival. CV disease accounted for 16.5% and 5% of potential years of life lost (PYLL) in male and female patients, respectively. The standard mortality ratio (SMR) following ischemic heart disease (IHD) was 3.9 in males and 3.8 in female patients, meaning an excess of IHD deaths observed, in comparison with the population of control. Conclusion. Prevention strategies based on CV risk factors, in particular in those patients with a previous history of CV disease, should be considered. (C) 2019 Elsevier B.V. All rights reserved.

Product ID:

113951

Handle IRIS:

11562/1015869

Last Modified:

November 28, 2022

Bibliographic citation:

Caocci, Giovanni; Mulas, Olga; Annunziata, Mario; Luciano, Luigiana; Abruzzese, Elisabetta; Bonifacio, Massimiliano; Orlandi, Ester Maria; Albano, Francesco; Galimberti, Sara; Iurlo, Alessandra; Pregno, Patrizia; Sgherza, Nicola; Martino, Bruno; Binotto, Gianni; Castagnetti, Fausto; Gozzini, Antonella; Bocchia, Monica; Fozza, Claudio; Stagno, Fabio; Simula, Maria Pina; De Gregorio, Fiorenza; Trawinska, Malgorzata Monika; Scaffidi, Luigi; Elena, Chiara; Attolico, Imma; Baratè, Claudia; Cattaneo, Daniele; Pirillo, Francesca; Gugliotta, Gabriele; Sicuranza, Anna; Molica, Matteo; La Nasa, Giorgio; Foà, Robin; Breccia, Massimo, Long-term mortality rate for cardiovascular disease in 656 chronic myeloid leukaemia patients treated with second- and third-generation tyrosine kinase inhibitors «International Journal of Cardiology» , vol. 301 , 2020 , pp. 163-166

Consulta la scheda completa presente nel repository istituzionale della Ricerca di Ateneo